Landmark New England Journal of Medicine Publication Reports Positive Results From PROMISE II Pivotal Trial Showing that LimFlow System Saves Most Patients with End-stage Peripheral Artery Disease From Major Amputation : vimarsana.com

Landmark New England Journal of Medicine Publication Reports Positive Results From PROMISE II Pivotal Trial Showing that LimFlow System Saves Most Patients with End-stage Peripheral Artery Disease From Major Amputation

PROMISE II Trial Met Primary Endpoint Therapy Demonstrates 76% Limb Salvage in Patients with Chronic Limb-Threatening Ischemia Who Otherwise Faced Amputation LimFlow SA, a pioneer in the

Related Keywords

Japan , Canada , United States , Americans , Tim Baker , Daniel Clair , Dan Rose , Michelle Mcadam , Mehdi Shishehbor , Chronic Communications Inc , Promise Ii Co , Vascular Institute , University Hospitals , Limb Salvage , New England Journal , Limflow System , Business Wire , Transcatheter Arterialization , Deep Veins , Principal Investigator , Harrington Heart , Vascular Surgery , Vanderbilt University Medical Center Section , Rutherford Stage , Chronic Limb Threatening Ischemia , Chronic Communications , Landmark , England , Ournal , Edicine , Ublication , Eports , Ositive , Esults , Rom , Romise , Ivotal , Rial , Howing , Limflow , Ystem , Aves , Ost , Atients , Tage , Peripheral , Artery , Isease , Ajor ,